Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Hypothesis:
Based on available pharmacokinetic data from healthy volunteers we hypothesize that the
administration of a cumulative dose of 210μg of the continuous erythropoietin receptor
activator, Mircera® (Roche), during 3 months post percutaneous coronary intervention (PCI)
does not result in hemoglobin (Hb) levels >15 g/dl in patients with ST-segment elevation
myocardial infarction (STEMI)
Design:
Prospective, open label single center pilot study